Skip to main content

Qing Cheng, PhD

Associate Professor in Surgery
Office: 203 Research Drive, 452 MSRB1, Durham, NC 27710
Campus Mail: DUMC Duke Box 2606, Durham, NC 27710

My research has been focusing on the development of methodologies and strategies to address the general question of human cancer heterogeneity and complexity, recognizing that clinical outcomes reflect a combination of contribution from the actual tumor but also the environment in which the tumor resides. By understanding who is at risk for recurrence, who is likely to respond to a given agent or regimen, and who is likely to exhibit an adverse event associated with a particular therapy, it will be possible to tailor therapeutic strategies to the characteristics of the individual patient as opposed to relying on the results of studies with heterogeneous populations of patients.

I made the original observation that gene copy number alterations (CNAs) in malignant cells can quantitatively affect gene function (Nat Genet 2005), and the contribution of this work to the field of cancer pharmacogenomics and personalized medicine was highly recognized by a "NEWS AND VIEWS" paper of Nature Genetics, in 2005. I demonstrated that clinical phenotypes can be affected by multiple forms of alterations (methylation, mutation, CNA) (Am J Hum Genet 2006), and genome-scan of CNAs followed by pathway analysis could uncover the novel gene interactions (Nat Med 2011). We developed a methodology that compiled a large collection of genomic data (Breast Cancer Res 2012) and demonstrated that uniquely characteristic of a clinical phenotype, such as dormancy, could be accessed using gene signature, a collection of multiple genetic alterations (Breast Cancer Res 2014).

Education and Training

  • Postdoctoral Research Associate, St. Jude Children's Research Hospital, 2001 - 2006
  • Ph.D., National University of Singapore, 2001

Publications

Cheng, Q, Li, X, Acharya, CR, Hyslop, T, and Sosa, JA. "A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors." Oncotarget 8, no. 10 (March 2017): 16690-16703.

Full Text

Price, TT, Burness, ML, Sivan, A, Warner, MJ, Cheng, R, Lee, CH, Olivere, L, Comatas, K, Magnani, J, Kim Lyerly, H, Cheng, Q, McCall, CM, and Sipkins, DA. "Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone." Science translational medicine 8, no. 340 (May 2016): 340ra73-.

Full Text

Price, TT, Lee, CH, Cheng, Q, Lyerly, HK, Fogler, WE, Magnani, JL, and Sipkins, DA. "Abstract 3212: Metastatic breast cancer cell communication within a pro-dormancy bone marrow niche." August 1, 2015.

Full Text

Gwin, WR, Hobeika, A, Osada, T, Hartman, Z, Cheng, Q, Broadwater, G, Kimmick, GG, Blackwell, KL, Morse, M, and Lyerly, K. "Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2." May 20, 2015.

Scholars@Duke

Yang, L-P, Zhang, A-L, Wang, D-D, Ke, H-X, Cheng, Q, and Wang, C. "Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin." Journal of clinical pharmacy and therapeutics 39, no. 4 (August 2014): 442-445.

Full Text

Cheng, Q, Chang, JT, Gwin, WR, Zhu, J, Ambs, S, Geradts, J, and Lyerly, HK. "A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype." Breast Cancer Research 16, no. 4 (July 25, 2014): 407-.

Full Text

Palena, C, Roselli, M, Litzinger, MT, Ferroni, P, Costarelli, L, Spila, A, Cavaliere, F, Huang, B, Fernando, RI, Hamilton, DH, Jochems, C, Tsang, K-Y, Cheng, Q, Lyerly, HK, Schlom, J, and Guadagni, F. "Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis." Journal of the National Cancer Institute 106, no. 5 (May 9, 2014).

Full Text

Xia, W, Petricoin, EF, Zhao, S, Liu, L, Osada, T, Cheng, Q, Wulfkuhle, JD, Gwin, WR, Yang, X, Gallagher, RI, Bacus, S, Lyerly, HK, and Spector, NL. "An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models." Breast Cancer Res 15, no. 5 (2013): R85-.

Full Text

Nair, S, Aldrich, AJ, McDonnell, E, Cheng, Q, Aggarwal, A, Patel, P, Williams, MM, Boczkowski, D, Lyerly, HK, Morse, MA, and Devi, GR. "Immunologic targeting of FOXP3 in inflammatory breast cancer cells." PLoS One 8, no. 1 (2013): e53150-.

Full Text

Cheng, Q, Chang, JT, Geradts, J, Neckers, LM, Haystead, T, Spector, NL, and Lyerly, HK. "Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. (Published online)" Breast Cancer Res 14, no. 2 (April 17, 2012): R62-.

Full Text

Pages